Insurance Status and Tumor Necrosis Factor Inhibitor Initiation Among Children With Juvenile Idiopathic Arthritis in the CARRA Registry

Jordan E. Roberts, Mary Beth F. Son(Boston Children's Hospital), Yongdong Zhao(Seattle Children's Hospital), Johnathan Dallas(Boston Children's Hospital), Livie Huie(University of Alabama at Birmingham), William Daniel Soulsby(University of California, San Francisco), Mary Eckert(Seattle Children's Hospital), Kathryn Williams(Boston Children's Hospital), Emily A. Smitherman(Children's of Alabama)
The Journal of Rheumatology
December 15, 2022
10.3899/jrheum.220871
Cited by 3

Related Papers

Multisystem Inflammatory Syndrome in U.S. Children and Adolescents
|New England Journal of Medicine|2020|2.7k
Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19
|JAMA|2021|852
Impaired Myocardial Flow Reserve on Rubidium-82 Positron Emission Tomography Imaging Predicts Adverse Outcomes in Patients Assessed for Myocardial Ischemia
|Journal of the American College of Cardiology|2011|602
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 1
|Arthritis & Rheumatology|2020|537
The Use of <sup>18</sup>F-FDG PET in the Diagnosis of Cardiac Sarcoidosis: A Systematic Review and Metaanalysis Including the Ontario Experience
|Journal of Nuclear Medicine|2012|512